OSI closes Eyetech deal in face of rivalry

Share this article:
OSI Pharmaceuticals didn't allow recent news from Genentech, which is developing a possible rival product, to spoil its planned takeover of eye-treatment firm Eyetech.
OSI said it acquired the company for about $685 million in cash and about 5.7 million shares of OSI common stock. The net value of the acquisition is about $650 million, after Eyetech's cash and net operating losses are factored in, OSI said.
Over the summer, Eyetech, whose sole product Macugen treats the wet form of age-related macular degeneration, agreed to sell itself for about $935 million. That deal had placed a
value on Eyetech of $20 a share. But last week OSI worried investors by saying it wanted extra time, prior to closing the buyout, to assess data from a Phase III trial of Genentech's experimental drug Lucentis (ranibizumab), also for wet age-related macular degeneration. In the trial,
the drug met its primary goal of maintaining vision in patients with the disease.
OSI released a statement over the weekend signaling its readiness to move ahead with the takeover.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...